GNPX
Genprex, Inc.
$0.49
+0.03 (+6.05%)
At close · Jul 15
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$84.69M
Shares
10,586,402
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.49
Open$0.46
Day$0.46–0.52
52W$0.42–55.00
Avg vol 30d336K
Short int938K · 8.9% float · 2.3d
Short vol44%
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−84%
below
Price vs 50-day avg
−27%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−83%
trailing
YTD return
−72%
this year
Relative strength
−93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
3 of 27 funds reported for Jun 30 · net -5.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.86% of float · ▼ -6.5% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — 13F breadth
Squeeze score
60
elevated · 0–100
Fundamentals
Free cash flow
$-15.3M
Balance sheet
$7.8M
net cash
Quant / Vol
risk profile
Volatility
273%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
12.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−84%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
3 of 27 funds reported for Jun 30 · net -5.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.86% of float · ▼ -6.5% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $55
vs 200-day avg -84%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GNPX
this stock
Genprex, Inc.
|
$84.69M | -71.9% | — | — | 8.9% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +2.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GNPX | -12.9% | +0.8% | -82.7% | -5.4% | -71.9% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -14.2% | +1.0% | -92.8% | -6.5% | -82.6% |